曾佳烽,李宝莹,潘俊芳,方通,吴光明
ZENG Jia-feng,LI Bao-ying,PAN Jun-fang,FANG Tong,WU Guang-ming

• 1:上海华拓医药科技发展有限公司

摘要(Abstract)：

目的鉴定肌酐-三氯氧磷缩合法生产的磷酸肌酸钠中一个新发现的杂质(1),并建立其含量测定方法。方法通过核磁共振、ESI高分辨质谱、X单晶衍射等光谱学方法解析该杂质1的结构;采用反相高效液相色谱法测定含量,使用C_(18)色谱柱,以乙腈-质量分数为0.2%的磷酸二氢钠水溶液(含质量分数为0.1%的四丁基氢氧化铵,磷酸或氨试液调节p H值至6.6)(体积比为20∶80)为流动相,检测波长:210 nm。结果杂质1鉴定为具焦磷酰结构的新化合物。反相高效液相色谱法的线性为0.25~100 mg·L~(-1);加样回收率,在磷酸肌酸钠粗品测定中为99.8%(RSD=1.1%,n=6),在精制品测定中为98.6%(RSD=1.6%,n=6)。结论对化学合成法来源的磷酸肌酸钠,可以用HPLC法来测定其中杂质1的含量。
Objective To separate and characterize a new impurity from crude phosphocreatine disodium that was manufactured by a Creatinine-Phosphorus oxychloride method,and to establish a method for its content determination. Methods The structure of the new impurity was elucidated via spectroscopic methods including 1D-and 2D-NMR spectra,and high-resolution ESI mass spectrometry,as well as single crystal Xray diffraction. Reversed phase high performance liquid chromatography( RP-HPLC) was chosen for the content determination of the impurity. The chromatographic seperation was performed on a C_(18) column in an isocratic mode using a mixture of acetonitrile and water phase( V ∶ V = 80) as the mobile phase with UV detection at 210 nm. The water phase containing 0. 2% sodium dihydrogen phosphate and 0. 1%tetrabutylammonium hydroxide was adjusted to pH 6. 6 with phosphoric acid or ammonia solution. Results The impurity was identified as a new compound( 1) bearing a pyrophosphoryl group. The linear range for 1 was 0. 25-100 mg·L~(-1). The recoveries were 99. 8%( RSD = 1. 1%,n = 6) in the crude phosphocreatine disodium,and 98. 6%( RSD = 1. 6%,n = 6) in the refined products. Conclusions The established RP-HPLC method is practical and applicable to control the content of 1 in phosphocreatine disodium products manufactured by chemical synthesis.

关键词(KeyWords)： 磷酸肌酸钠;杂质;结构鉴定;含量测定
phosphocreatine disodium;impurity;structure identification;content determination

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 曾佳烽,李宝莹,潘俊芳,方通,吴光明
ZENG Jia-feng,LI Bao-ying,PAN Jun-fang,FANG Tong,WU Guang-ming

DOI: 10.14066/j.cnki.cn21-1349/r.2017.07.004

参考文献(References)：

• [1]许夕霞,檀碧波,宿桂霞,等.磷酸肌酸钠对胃癌术后疲劳综合征患者免疫功能的影响[J].中国中西医结合外科杂志,2014,20(2):120-123.
• [2]林文辉,林雪华,谢彬.注射用膦酸肌酸钠对含阿霉素类化疗的120例恶性肿瘤患者生活质量改善的研究[J].海峡药学,2010,22(6):123-124.
• [3]王叨,刘玉峰,张敬芳,等.磷酸肌酸钠防治儿童急性白血病蒽环类药物所致急性心脏毒性的临床观察[J].中国妇幼保健,2013,28:2216-2218.
• [4]赵莉,王俊兰,白丽亚.磷酸肌酸钠治疗黄疸早产儿心肌损伤的临床研究[J].中国妇幼保健,2011,26(10):1550-1553.
• [5]牛玲,安新江,田静,等.儿童病毒性心肌炎124例临床分析[J].临床医学,2013,33(3):72-74.
• [6]ZHANG Jian-jiang,ZENG Hui-qin,WANG Na,et al.Beneficial effects of creatine phosphate sodium for the treatment of Henoch-Scho¨nlein purpura in patients with early renal damage detected using urinary kidney injury molecule-1 levels[J].Eur J Pediatr,2016,175(1):49-55.
• [7]练美华.磷酸肌酸钠的合成[J].中国医药工业杂志,2013,44(7):655-657.
• [8]吕伟,张秋华,朱勤,等.药用磷酸肌酸二钠盐六水合物及其制备方法:200710038838.X[P].2009-05-20.
• [9]国家药典委员会.中华人民共和国药典:二部[M].北京:中国医药科技出版社,2015:1568-1569.